Journal article · 2025 · Open access

Bivalent prefusion F vaccination in pregnancy and respiratory syncytial virus hospitalisation in infants in the UK: results of a multicentre, test-negative, case-control study

Thomas Williams, Robin D. Marlow, Steve Cunningham, Simon B. Drysdale, Helen Elizabeth Groves, Samantha Hunt, Dalia Iskander, Xinxue Liu, Mark David Lyttle, Chengetai D Mpamhanga, Shaun O’Hagan, Thomas Waterfield and 122 more

The Lancet Child & Adolescent Health, 9(9), 655–662 · Published 18 July 2025 · DOI 10.1016/s2352-4642(25)00155-5

Open full textCite this paper

In brief

“Bivalent prefusion F vaccination in pregnancy and respiratory syncytial virus hospitalisation in infants in the UK: results of a multicentre, test-negative, case-control study” is a 2025 journal article by Thomas Williams and 133 co-authors, published in The Lancet Child & Adolescent Health. OpenAlex counts 65 citations as of 18 November 2026, which puts it in the top 1% of works published in 2025 by citations. It is open access under a CC BY licence: the full text is free to read at The Lancet Child & Adolescent Health.

Citations
65
Most cited in
2026 (51)
Field-weighted impact
33.20
References
23
Authors
134

Abstract

BACKGROUND: Respiratory syncytial virus (RSV) is the leading cause of acute lower respiratory infections (ALRI) in infants younger than 6 months globally. A maternal bivalent RSV prefusion F (RSVpreF) vaccine was introduced to the UK in late summer in 2024 (August 12 in Scotland and September 1 in England), with all pregnant women at 28 weeks or more of gestation eligible for vaccination. We aimed to understand RSVpreF vaccine effectiveness in a real-world setting. METHODS: We conducted a multicentre, test-negative, case-control study to analyse the vaccine effectiveness of maternal RSVpreF vaccination against the primary outcome of hospitalisation (ie, admission to hospital) for RSV-associated ALRI in infants. Patient and public involvement from a group of parents informed the study protocol design. Included patients were infants with ALRI born after Aug 12, 2024 (Scotland), and Sept 1, 2024 (England), and therefore had mothers eligible for maternal vaccination, who were admitted to 30 hospital sites across the UK from Sept 30, 2024, to Jan 20, 2025, and tested for RSV. Infants were followed up until hospital discharge or death as an inpatient. Primary vaccine effectiveness of maternal RSVpreF vaccination against RSV-associated hospitalisation was calculated with the use of a conditional logistic regression adjusted by site, calendar month of hospital attendance for the infant, age, preterm birth, and sex. FINDINGS: We included 537 mother-infant pairs, in whom there were 391 RSV-positive infant cases (median age 1·63 months [IQR 0·94-2·26]) and 146 RSV-negative infant controls (1·41 months [0·77-2·03]). Of 537 recruited infants, 297 (55%) were male and 240 (45%) were female. Ethnicity data were available for 533 mothers, of whom 434 (81%) self-identified as White. The mothers of 73 (19%) RSV-positive cases and 60 (41%) RSV-negative controls had received RSVpreF vaccine before delivery. The adjusted effectiveness of maternal RSVpreF vaccination for preventing infant hospitalisation was 58% (95% CI 28-75) for infants whose mothers were vaccinated at any time before delivery and 72% (48-85) for infants whose mothers were vaccinated more than 14 days before delivery (39 [11%] of 357 RSV-positive cases vs 43 [33%] of 129 RSV-negative controls). INTERPRETATION: In the real-world setting of the first season of vaccine implementation in England and Scotland, maternal RSVpreF vaccination was effective and equivalent to trial settings in reducing the risk of hospitalisation in infants with RSV-associated ALRI. FUNDING: National Institute for Health and Care Research, The Wellcome Trust, and Imperial College London.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Williams, T., Marlow, R. D., Cunningham, S., Drysdale, S. B., Groves, H. E., Hunt, S., Iskander, D., Liu, X., Lyttle, M. D., Mpamhanga, C. D., O’Hagan, S., Waterfield, T., Roland, D., Middleton, C. M., Connon, M., Paxton, J. M., Thomson, N., Baker, J. T., Hardwick, S. R., . . . Beeby, D. (2025). Bivalent prefusion F vaccination in pregnancy and respiratory syncytial virus hospitalisation in infants in the UK: results of a multicentre, test-negative, case-control study. The Lancet Child & Adolescent Health, 9(9), 655–662. https://doi.org/10.1016/s2352-4642(25)00155-5

MLA 9

Williams, Thomas, et al. “Bivalent prefusion F vaccination in pregnancy and respiratory syncytial virus hospitalisation in infants in the UK: results of a multicentre, test-negative, case-control study.” The Lancet Child & Adolescent Health, vol. 9, no. 9, 2025, pp. 655–662. https://doi.org/10.1016/s2352-4642(25)00155-5.

Chicago

Williams, Thomas, Robin D. Marlow, Steve Cunningham, Simon B. Drysdale, Helen Elizabeth Groves, Samantha Hunt, Dalia Iskander, et al. 2025. “Bivalent prefusion F vaccination in pregnancy and respiratory syncytial virus hospitalisation in infants in the UK: results of a multicentre, test-negative, case-control study.” The Lancet Child & Adolescent Health 9 (9): 655–662. https://doi.org/10.1016/s2352-4642(25)00155-5.

Harvard

Williams, T. et al. (2025) ‘Bivalent prefusion F vaccination in pregnancy and respiratory syncytial virus hospitalisation in infants in the UK: results of a multicentre, test-negative, case-control study’, The Lancet Child & Adolescent Health, 9(9), pp. 655–662. doi:10.1016/s2352-4642(25)00155-5.

IEEE

T. Williams et al., “Bivalent prefusion F vaccination in pregnancy and respiratory syncytial virus hospitalisation in infants in the UK: results of a multicentre, test-negative, case-control study,” The Lancet Child & Adolescent Health, vol. 9, no. 9, pp. 655–662, 2025, doi: 10.1016/s2352-4642(25)00155-5.

BibTeX

@article{williams2025bivalent,
  title     = {{Bivalent prefusion F vaccination in pregnancy and respiratory syncytial virus hospitalisation in infants in the UK: results of a multicentre, test-negative, case-control study}},
  author    = {Williams, Thomas and Marlow, Robin D. and Cunningham, Steve and Drysdale, Simon B. and Groves, Helen Elizabeth and Hunt, Samantha and Iskander, Dalia and Liu, Xinxue and Lyttle, Mark David and Mpamhanga, Chengetai D and O’Hagan, Shaun and Waterfield, Thomas and Roland, Damian and Middleton, Catriona M and Connon, Maggie and Paxton, Jill M and Thomson, Nicola and Baker, James Thomas and Hardwick, Susie R and Fraser, Karena Jan and Kimber, Kathryn Frances and French, Asa JE and Tolhurst-Cleaver, Meriel FJ and Siner, Sarah and Fletcher, Stephen and Geoghegan, Karen and Tremarco, Laura Ann and Curran, Kelly and Diaba, Cynthia Dzokoto and Iheanetu-Oguejiofor, Chidinma Joanne and others},
  journal   = {The Lancet Child \& Adolescent Health},
  year      = {2025},
  volume    = {9},
  number    = {9},
  pages     = {655--662},
  doi       = {10.1016/s2352-4642(25)00155-5},
  url       = {https://doi.org/10.1016/s2352-4642(25)00155-5}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Health Sciences › Medicine › Epidemiology › Respiratory viral infections research

  • respiratory syncytial virus
  • RSVpreF vaccine
  • prefusion F protein
  • maternal immunization
  • pregnancy
  • infant hospitalization
  • acute lower respiratory tract infection
  • vaccine effectiveness

Work with this paper

Most-cited papers in Medicine

All highly cited Medicine papers

Questions about this paper

How do I cite this paper in APA style?

Williams, T., Marlow, R. D., Cunningham, S., Drysdale, S. B., Groves, H. E., Hunt, S., Iskander, D., Liu, X., Lyttle, M. D., Mpamhanga, C. D., O’Hagan, S., Waterfield, T., Roland, D., Middleton, C. M., Connon, M., Paxton, J. M., Thomson, N., Baker, J. T., Hardwick, S. R., . . . Beeby, D. (2025). Bivalent prefusion F vaccination in pregnancy and respiratory syncytial virus hospitalisation in infants in the UK: results of a multicentre, test-negative, case-control study. The Lancet Child & Adolescent Health, 9(9), 655–662. https://doi.org/10.1016/s2352-4642(25)00155-5

How many times has this paper been cited?

65 times, according to OpenAlex on 18 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at The Lancet Child & Adolescent Health: sign in and open the full text from this page.

Who wrote this paper?

Thomas Williams, Robin D. Marlow, Steve Cunningham, Simon B. Drysdale, Helen Elizabeth Groves, Samantha Hunt, Dalia Iskander, Xinxue Liu, Mark David Lyttle, Chengetai D Mpamhanga, Shaun O’Hagan, Thomas Waterfield and 122 more.

What is the DOI of this paper?

10.1016/s2352-4642(25)00155-5, permanently at https://doi.org/10.1016/s2352-4642(25)00155-5. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 18 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.